WO2019054809A3 - 자가면역질환 및 골질환 치료제로서의 펩타이드의 용도 - Google Patents

자가면역질환 및 골질환 치료제로서의 펩타이드의 용도 Download PDF

Info

Publication number
WO2019054809A3
WO2019054809A3 PCT/KR2018/010874 KR2018010874W WO2019054809A3 WO 2019054809 A3 WO2019054809 A3 WO 2019054809A3 KR 2018010874 W KR2018010874 W KR 2018010874W WO 2019054809 A3 WO2019054809 A3 WO 2019054809A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
diseases
therapeutic agent
cells
autoimmune diseases
Prior art date
Application number
PCT/KR2018/010874
Other languages
English (en)
French (fr)
Other versions
WO2019054809A2 (ko
Inventor
조대호
김경은
김면수
박선영
정희영
Original Assignee
주식회사 바이오펩
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202311703344.4A priority Critical patent/CN117777238A/zh
Application filed by 주식회사 바이오펩 filed Critical 주식회사 바이오펩
Priority to CA3075471A priority patent/CA3075471C/en
Priority to US16/645,957 priority patent/US11730788B2/en
Priority to EP18857032.9A priority patent/EP3682891A4/en
Priority to CN201880059599.2A priority patent/CN111093687A/zh
Priority to JP2020515095A priority patent/JP2020533375A/ja
Priority to AU2018333776A priority patent/AU2018333776B2/en
Priority claimed from KR1020180110485A external-priority patent/KR102166927B1/ko
Priority claimed from KR1020180110481A external-priority patent/KR102166928B1/ko
Publication of WO2019054809A2 publication Critical patent/WO2019054809A2/ko
Publication of WO2019054809A3 publication Critical patent/WO2019054809A3/ko
Priority to JP2022085612A priority patent/JP7408175B2/ja
Priority to US18/300,230 priority patent/US20240009264A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 치료제로서의 펩타이드의 용도에 관한 것으로, 본 발명의 펩타이드들은 자가면역질환에 관련된 T 세포(T cell)의 활성 및 Th17 세포(T helper 17 cell) 분화를 유의적으로 억제시키고, 염증성 사이토카인 IL-6 분비를 감소시키며, 관절염 동물모델에서 현저한 관절염 치료 및 개선 효과를 갖는 것을 확인하였으므로, 상기 펩타이드들은 골질환, 염증성 질환 또는 류마티스 관절염과 같은 다양한 자가면역질환 치료제에 유효성분으로 이용될 수 있다.
PCT/KR2018/010874 2017-09-15 2018-09-14 자가면역질환 및 골질환 치료제로서의 펩타이드의 용도 WO2019054809A2 (ko)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2020515095A JP2020533375A (ja) 2017-09-15 2018-09-14 自己免疫疾患および骨疾患の治療剤としてのペプチドの用途
CA3075471A CA3075471C (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
US16/645,957 US11730788B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
EP18857032.9A EP3682891A4 (en) 2017-09-15 2018-09-14 USE OF PEPTIDES AS A THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES
CN201880059599.2A CN111093687A (zh) 2017-09-15 2018-09-14 作为自身免疫疾病及骨病治疗剂的肽的用途
CN202311703344.4A CN117777238A (zh) 2017-09-15 2018-09-14 作为自身免疫疾病及骨病治疗剂的肽的用途
AU2018333776A AU2018333776B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
JP2022085612A JP7408175B2 (ja) 2017-09-15 2022-05-25 自己免疫疾患および骨疾患の治療剤としてのペプチドの用途
US18/300,230 US20240009264A1 (en) 2017-09-15 2023-04-13 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2017-0118952 2017-09-15
KR10-2017-0118950 2017-09-15
KR20170118950 2017-09-15
KR20170118952 2017-09-15
KR10-2018-0110485 2018-09-14
KR1020180110481A KR102166928B1 (ko) 2017-09-15 2018-09-14 골질환 치료제로서의 펩타이드의 용도
KR10-2018-0110481 2018-09-14
KR1020180110485A KR102166927B1 (ko) 2017-09-15 2018-09-14 자가면역질환 치료제로서의 펩타이드의 용도

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/645,957 A-371-Of-International US11730788B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
US18/300,230 Continuation US20240009264A1 (en) 2017-09-15 2023-04-13 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

Publications (2)

Publication Number Publication Date
WO2019054809A2 WO2019054809A2 (ko) 2019-03-21
WO2019054809A3 true WO2019054809A3 (ko) 2019-06-06

Family

ID=65723727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/010874 WO2019054809A2 (ko) 2017-09-15 2018-09-14 자가면역질환 및 골질환 치료제로서의 펩타이드의 용도

Country Status (1)

Country Link
WO (1) WO2019054809A2 (ko)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195141A1 (en) * 2002-02-04 2003-10-16 Ronald Mathison Anti-inflammatory peptides
KR101029705B1 (ko) * 2010-06-30 2011-04-18 (주)엔솔테크 신규 펩타이드 및 그 용도
KR20140005110A (ko) * 2012-07-03 2014-01-14 일양약품주식회사 신규한 펩타이드 및 이의 용도
US20160168202A1 (en) * 2007-10-12 2016-06-16 King's College London Cyclic peptides as ADAM protease inhibitors
WO2017155234A1 (ko) * 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195141A1 (en) * 2002-02-04 2003-10-16 Ronald Mathison Anti-inflammatory peptides
US20160168202A1 (en) * 2007-10-12 2016-06-16 King's College London Cyclic peptides as ADAM protease inhibitors
KR101029705B1 (ko) * 2010-06-30 2011-04-18 (주)엔솔테크 신규 펩타이드 및 그 용도
KR20140005110A (ko) * 2012-07-03 2014-01-14 일양약품주식회사 신규한 펩타이드 및 이의 용도
WO2017155234A1 (ko) * 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3682891A4 *

Also Published As

Publication number Publication date
WO2019054809A2 (ko) 2019-03-21

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2020005041A (es) Agonistas parciales de interleucina-2.
PH12019500349A1 (en) Diacylglycerol acyltransferase 2 inhibitors
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
SG10201909093XA (en) Mixed allergen compositions and methods for using the same
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
PH12019550263A1 (en) A Pharmaceutical Composition for Anaemia
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
MX2021010144A (es) Formulaciones farmaceuticas.
MX2020009999A (es) Composiciones farmacéuticas para inhibir citocinas inflamatorias.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18857032

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3075471

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020515095

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018333776

Country of ref document: AU

Date of ref document: 20180914

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018857032

Country of ref document: EP

Effective date: 20200415